Abhishek Kumar1,2, Rajany Dy3, Kanwaljit Singh4, M Jeffery Mador3,5. 1. Mercy Medical Center, Cedar Rapids, IA, USA. medshek@gmail.com. 2. State University of New York/University at Buffalo, Buffalo, NY, USA. medshek@gmail.com. 3. State University of New York/University at Buffalo, Buffalo, NY, USA. 4. University of Massachusetts, Worcester, MA, USA. 5. Western New York Veterans Administration Healthcare System, Buffalo, NY, USA.
Abstract
INTRODUCTION: The goal of our systematic review and meta-analysis is to examine the therapeutic effectiveness of bronchoscopic lung volume reduction (BLVR), and to compare it with medical management and lung volume reduction surgery. METHODS: Variables of interest were absolute change in FEV1, 6MWT, and SGRQ. Meta-analysis was performed for the BLVR modalities with ≥3 trials. Of the 18 shortlisted publications, only valves (four trials; n = 159) and coils (six trials; n = 194) qualified for meta-analysis. To avoid redundant reporting for valves, only the data for intact fissure subjects were analyzed. Outcome data are presented as the mean difference from baseline with 95% confidence interval at 6-months follow-up. RESULTS: For BLVR using valves, the pooled mean difference (PMD) for FEV1 was 0.146 L (95% CI 0.111-0.181; p < 0.001), 6MWT was 45.225 meters (95% CI 26.954-63.495; p < 0.001), and SGRQ was -8.825 points (95% CI -14.824 to -2.825; p = 0.004). All the PMDs were statistically significant and higher than their respective minimal clinically important difference (MCID). For BLVR using coils, the PMD for FEV1 was 0.080 L (95% CI 0.057-0.104; p < 0.001), 6MWT was 45.320 meters (95% CI 28.040-62.600; p < 0.001), and SGRQ was -10.570 points (95% CI -13.299 to -7.841; p < 0.001). All three variables showed statistically significant PMDs but that for FEV1 was smaller than the MCID. Data from BLVR modalities with <3 major publications are reviewed in the discussion section. CONCLUSIONS: BLVR offers early promise in the palliation of advanced emphysema. Better characterization of patients to identify phenotypes that will derive sustained benefit is needed.
INTRODUCTION: The goal of our systematic review and meta-analysis is to examine the therapeutic effectiveness of bronchoscopic lung volume reduction (BLVR), and to compare it with medical management and lung volume reduction surgery. METHODS: Variables of interest were absolute change in FEV1, 6MWT, and SGRQ. Meta-analysis was performed for the BLVR modalities with ≥3 trials. Of the 18 shortlisted publications, only valves (four trials; n = 159) and coils (six trials; n = 194) qualified for meta-analysis. To avoid redundant reporting for valves, only the data for intact fissure subjects were analyzed. Outcome data are presented as the mean difference from baseline with 95% confidence interval at 6-months follow-up. RESULTS: For BLVR using valves, the pooled mean difference (PMD) for FEV1 was 0.146 L (95% CI 0.111-0.181; p < 0.001), 6MWT was 45.225 meters (95% CI 26.954-63.495; p < 0.001), and SGRQ was -8.825 points (95% CI -14.824 to -2.825; p = 0.004). All the PMDs were statistically significant and higher than their respective minimal clinically important difference (MCID). For BLVR using coils, the PMD for FEV1 was 0.080 L (95% CI 0.057-0.104; p < 0.001), 6MWT was 45.320 meters (95% CI 28.040-62.600; p < 0.001), and SGRQ was -10.570 points (95% CI -13.299 to -7.841; p < 0.001). All three variables showed statistically significant PMDs but that for FEV1 was smaller than the MCID. Data from BLVR modalities with <3 major publications are reviewed in the discussion section. CONCLUSIONS: BLVR offers early promise in the palliation of advanced emphysema. Better characterization of patients to identify phenotypes that will derive sustained benefit is needed.
Authors: Felix J F Herth; Marc Noppen; Arschang Valipour; Sylvie Leroy; Jean-Michel Vergnon; Joachim H Ficker; Jim J Egan; Stefano Gasparini; Carlos Agusti; Debby Holmes-Higgin; Armin Ernst Journal: Eur Respir J Date: 2012-01-26 Impact factor: 16.671
Authors: Federico Venuta; Marco Anile; Daniele Diso; Carolina Carillo; Tiziano De Giacomo; Antonio D'Andrilli; Francesco Fraioli; Erino A Rendina; Giorgio F Coloni Journal: Eur Respir J Date: 2011-10-17 Impact factor: 16.671
Authors: Dirk-Jan Slebos; Jorine E Hartman; Karin Klooster; Stefan Blaas; Gaetan Deslee; Wolfgang Gesierich; Juergen Hetzel; Martin Hetzel; William McNulty; Samuel V Kemp; Romain Kessler; Sylvie Leroy; Franz Stanzel; Christian Witt; Zaid Zoumot; Felix J F Herth; Pallav L Shah Journal: Respiration Date: 2015-06-25 Impact factor: 3.580
Authors: Karin Klooster; Nick H T ten Hacken; Jorine E Hartman; Huib A M Kerstjens; Eva M van Rikxoort; Dirk-Jan Slebos Journal: N Engl J Med Date: 2015-12-10 Impact factor: 91.245